- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07631286
Ejaculatory-Sparing HoLEP vs Standard HoLEP
Ejaculatory-sparing Holmium Laser Enucleation of the Prostate (HoLEP) vs Standard HoLEP: a Randomized Controlled Trial
Studieoversigt
Status
Intervention / Behandling
Detaljeret beskrivelse
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Alyssa McDonald, MPH
- Telefonnummer: 312-695-8146
- E-mail: alyssa.mcdonald@northwestern.edu
Studiesteder
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60611
- Rekruttering
- Northwestern University
-
Ledende efterforsker:
- Amy E Krambeck, MD
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
- Patients who are sexually active with antegrade ejaculation who are undergoing HoLEP for the treatment of bothersome lower urinary tract symptoms.
Exclusion Criteria:
- Patients with pre-existing retrograde ejaculation
- Patients who are not sexually active
- Patients with indwelling urinary catheter prior to surgery, neurological disease, or history of prior prostatic/urethral surgery that may impact ejaculation
- Patients who lack decisional capacity
- Patients unable to read/speak English
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Ingen indgriben: Standard HoLEP
HoLEP procedure performed using standard care technique.
|
|
|
Aktiv komparator: ES-HoLEP
HoLEP procedure performed using ejaculatory-sparing HoLEP technique.
|
The ejaculatory sparing technique involves sparing the distal apex of the prostate in particular the anterior portion of the prostate which will allow for coaptation necessary for antegrade ejaculation.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of retrograde ejaculation
Tidsramme: 1 year
|
Patient reported incidence of experiencing retrograde ejaculation
|
1 year
|
|
Ejaculatory satisfaction
Tidsramme: 1 year
|
Patient reported satisfaction of ejaculation using Male Sexual Health Questionnaire - Ejaculatory Dysfunction (MSHQ-EjD) questionnaire. The MSHQ-EjD-SF evaluates the following parameters in regards to ejaculation: Frequency, Force, Volume and Bother (How much are you bothered by any ejaculation difficulties) on a 6-point Likert scale (typically scored 0 to 5). Interpretation: Higher scores indicate better ejaculatory function, while lower scores denote dysfunction and a greater level of personal distress regarding one's ejaculatory function. |
1 year
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Sexual satisfaction
Tidsramme: 1 year
|
Patient reported sexual satisfaction using the Sexual Health Inventory for Men (SHIM) questionnaire. The Sexual Health Inventory for Men (SHIM) contains 5 questions that is individually scored on a scale of 0 to 5. The SHIM score is calculated by adding up the scores of the 5 individual questions. Interpretation: Higher scores indicate better erectile function, while lower scores denote erectile dysfunction. A total score of 21 or less indicates that erectile dysfunction is present and should be addressed with a healthcare provider. |
1 year
|
|
Urinary satisfaction
Tidsramme: 1 year
|
Patient reported urinary satisfaction using the International Prostate Symptom Score (IPSS) questionnaire. The International Prostate Symptom Score (IPSS) is calculated by asking patients to rate 7 urinary symptoms over the past month on a scale from 0 to 5. These scores are simply added together to yield a total symptom severity score ranging from 0 to 35. An 8th question measures overall Quality of Life (QoL) but is not factored into the numerical total. Interpretation: the total score range is from 0 to 35. The total score indicates symptom severity: 0-7: Mildly symptomatic 8-19: Moderately symptomatic 20-35: Severely symptomatic |
1 year
|
|
Urinary satisfaction
Tidsramme: 1 year
|
Patient reported urinary satisfaction using the Michigan Incontinence Symptom Index (M-ISI) questionnaires. The M-ISI (Michigan Incontinence Symptom Index) questionnaire is a 10-item clinical tool used to evaluate the severity of urinary incontinence and how much it bothers the patient. It is calculated by assigning scores (0 to 4) to each answer and summing them across two primary domains. Total M-ISI Severity Domain (Items 1-8): Sum of the scores for the first 8 questions. This evaluates incontinence subdomains (Stress Urinary Incontinence, Urgency Urinary Incontinence, and Pad Use). Possible score range 0 to 32. Bother Domain (Items 9-10): Sum of the scores for questions 9 and 10. This measures the emotional and physical impact of the leakage. Possible score range 0 to 8. Interpretation: Higher scores indicate the individual is likely incontinent or has experience with incontinence. |
1 year
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Amy E Krambeck, MD, Northwestern University
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- STU00225807
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Forstørret prostata (BPH)
-
Smita DeRekrutteringBPH med urinvejsobstruktion | BPH med symptomatiske nedre urinvejssymptomerForenede Stater
-
Boston Scientific CorporationAfsluttetBPH | BPH med urinvejsobstruktion | BPH med urinvejsobstruktion med andre nedre urinvejssymptomerForenede Stater, Australien
-
Shanghai East HospitalIkke rekrutterer endnu
-
Yonsei UniversityAfsluttet
-
National Taiwan University HospitalAfsluttet
-
Assiut UniversityIkke rekrutterer endnu
-
Centre hospitalier de l'Université de Montréal...Afsluttet
-
University of North Carolina, Chapel HillBTG International Inc.Afsluttet
Kliniske forsøg med Ejaculatory-sparing (ES-sparing) HoLEP
-
Varian, a Siemens Healthineers CompanyRekrutteringProstatakræftForenede Stater, Spanien, Tyskland
-
Bradley NeedlemanAfsluttet
-
Massachusetts General HospitalAfsluttetSmåcellet lungekarcinom | Ikke-småcellet lungekarcinomForenede Stater
-
M.D. Anderson Cancer CenterAfsluttetBrystkræftForenede Stater
-
Fondazione del Piemonte per l'OncologiaRekrutteringRektal Adenocarcinom | Ikke -metastatiskItalien
-
Jona Hattangadi-GluthNational Cancer Institute (NCI); National Institutes of Health (NIH)RekrutteringKræft | Hjernemetastaser, voksen | Neurokognitiv funktionForenede Stater
-
Peking University People's HospitalRekruttering
-
Brust-Zentrum AGAfsluttet
-
Institut de Cancérologie de LorraineRekrutteringKnoglemetastase | Onkologisk smerteFrankrig